nimesulide has been researched along with Cardiovascular Diseases in 2 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors ('statins') and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') and increase in cardiovascular risk." | 3.74 | Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. ( Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zolotovskaya, IA | 1 |
| Davydkin, IL | 1 |
| Motola, D | 1 |
| Vargiu, A | 1 |
| Leone, R | 1 |
| Conforti, A | 1 |
| Moretti, U | 1 |
| Vaccheri, A | 1 |
| Velo, G | 1 |
| Montanaro, N | 1 |
1 trial available for nimesulide and Cardiovascular Diseases
| Article | Year |
|---|---|
[Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
Topics: Acute Pain; Aged; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cardiovascular Diseases; Cyclo | 2015 |
1 other study available for nimesulide and Cardiovascular Diseases
| Article | Year |
|---|---|
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2008 |